Abstract:
Patients with morbid obesity (MO) have a high risk of thromboembolic events. In patients with a BMI >35, the hypercoagulable state is due to impairment of all parts of the blood coagulation as well as anticoagulation mechanisms by obesity. Combined therapy of thromboembolic complications in patients with obesity Sodium Enoxaparin sodium and Pentoxifylline is more effective than Enoxaparin sodium monotherapy because it affects all parts of the hemostatic system.
